Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Australian trial of behavioural activation for people with schizophrenia experiencing negative symptoms: a feasibility randomised controlled trial protocol.

  • Authors : Muyambi K; Department of Rural Health, University of South Australia, Whyalla Norrie, South Australia, Australia .; Walsh S

Subjects: Schizophrenia*/Schizophrenia*/Schizophrenia*/therapy ; Feasibility Studies* ; Quality of Life*

  • Source: BMJ open [BMJ Open] 2024 May 06; Vol. 14 (5), pp. e080245. Date of Electronic Publication: 2024 May 06.Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Cognitive remediation for schizophrenia: Clinician perspectives on implementation barriers and facilitators.

  • Authors : Altman RAE; Centre for Mental Health and Brain Sciences, School of Health Sciences, Swinburne University of Technology.; Reser M

Subjects: Schizophrenia*/Schizophrenia*/Schizophrenia*/rehabilitation ; Schizophrenia*/Schizophrenia*/Schizophrenia*/complications ; Cognitive Remediation*/Cognitive Remediation*/Cognitive Remediation*/methods

  • Source: Rehabilitation psychology [Rehabil Psychol] 2024 May; Vol. 69 (2), pp. 171-183. Date of Electronic Publication: 2024 Mar 21.Publisher: Country of Publication: United States NLM ID: 0365337 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1939-1544

Record details

×
Academic Journal

Alteration of DNA Methylation and Epigenetic Scores Associated With Features of Schizophrenia and Common Variant Genetic Risk.

  • Authors : Kiltschewskij DJ; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia; Precision Medicine Program, Hunter Medical Research Institute, New Lambton, New South Wales, Australia.

Subjects: DNA Methylation* ; Schizophrenia*/Schizophrenia*/Schizophrenia*/genetics; Humans

  • Source: Biological psychiatry [Biol Psychiatry] 2024 Apr 01; Vol. 95 (7), pp. 647-661. Date of Electronic Publication: 2023 Jul 20.Publisher: Elsevier Country of Publication: United States NLM ID: 0213264 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

Obesity as a potential confounder of clozapine-induced myocarditis in the Hunter region of Australia.

  • Authors : Kikuchi Y; Department of Psychiatry, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan; Department of Psychiatry, Kodama Hospital, Ishinomaki, Miyagi, Japan. Electronic address: .

Subjects: Clozapine*/Clozapine*/Clozapine*/adverse effects ; Myocarditis*/Myocarditis*/Myocarditis*/chemically induced ; Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/adverse effects

  • Source: Schizophrenia research [Schizophr Res] 2024 May; Vol. 267, pp. 42-43. Date of Electronic Publication: 2024 Mar 21.Publisher: Elsevier Science Publisher B. V Country of Publication: Netherlands NLM ID: 8804207 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Seven decades of antipsychotic drugs: Why is the life of Australians with schizophrenia still so suboptimal?

  • Authors : Castle D; Department of Psychiatry, University of Tasmania, Hobart, TAS, Australia.; Copolov D

Subjects: Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/therapeutic use ; Schizophrenia*/Schizophrenia*/Schizophrenia*/drug therapy ; Psychotic Disorders*/Psychotic Disorders*/Psychotic Disorders*/drug therapy

  • Source: The Australian and New Zealand journal of psychiatry [Aust N Z J Psychiatry] 2024 Mar; Vol. 58 (3), pp. 201-206. Date of Electronic Publication: 2023 Dec 21.Publisher: Sage Country of Publication: England NLM ID: 0111052 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1440-1614

Record details

×
Academic Journal

Examining the clinical effectiveness of continuation and maintenance electroconvulsive therapy in schizophrenia.

  • Authors : George R; Western Sydney Local Health District, Westmead, NSW 2145, Australia.; Krishnan V

Subjects: Schizophrenia*/Schizophrenia*/Schizophrenia*/drug therapy ; Electroconvulsive Therapy*; Humans

  • Source: Asian journal of psychiatry [Asian J Psychiatr] 2024 Feb; Vol. 92, pp. 103895. Date of Electronic Publication: 2023 Dec 25.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101517820 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial.

  • Authors : Weickert TW; Neuroscience Research Australia, Sydney, New South Wales, Australia; School of Psychiatry and Mental Health, University of New South Wales, Sydney, New South Wales, Australia. Electronic address: .

Subjects: Schizophrenia*/Schizophrenia*/Schizophrenia*/drug therapy; Humans ; C-Reactive Protein/C-Reactive Protein/C-Reactive Protein/analysis

  • Source: Brain, behavior, and immunity [Brain Behav Immun] 2024 Jan; Vol. 115, pp. 191-200. Date of Electronic Publication: 2023 Oct 15.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8800478 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Community Pharmacists' Role in Reducing the Incidence of Cardiometabolic Adverse Drug Events in Schizophrenia: Insights from Mental Health Professionals.

  • Authors : Karge RA; School of Pharmacy and Pharmacology, College of Health and Medicine, University of Tasmania, Hobart, TAS 7005, Australia.; Curtain CM

Subjects: Schizophrenia*/Schizophrenia*/Schizophrenia*/drug therapy ; Drug-Related Side Effects and Adverse Reactions* ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/prevention & control

  • Source: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2023 Nov 21; Vol. 59 (12). Date of Electronic Publication: 2023 Nov 21.Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144

Record details

×
Academic Journal

Cadence discovery: study protocol for a dose-finding and mechanism of action clinical trial of sodium benzoate in people with treatment-refractory schizophrenia.

  • Authors : Baker A; QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.; Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, QLD, Australia.

Subjects: Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/adverse effects ; Schizophrenia*/Schizophrenia*/Schizophrenia*/diagnosis ; Schizophrenia*/Schizophrenia*/Schizophrenia*/drug therapy

  • Source: Trials [Trials] 2021 Dec 13; Vol. 22 (1), pp. 918. Date of Electronic Publication: 2021 Dec 13.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

Record details

×
Academic Journal

Development and initial validation of a multivariable predictive Early Adversity Scale for Schizophrenia (EAS-Sz) using register data to quantify environmental risk for adult schizophrenia diagnosis after childhood exposure to adversity.

  • Authors : Di Prinzio P; Neuropsychiatric Epidemiology Research Unit, School of Population and Global Health, The University of Western Australia, Perth, Australia.; Björk J

Subjects: Schizophrenia*/Schizophrenia*/Schizophrenia*/diagnosis ; Schizophrenia*/Schizophrenia*/Schizophrenia*/epidemiology ; Schizophrenia*/Schizophrenia*/Schizophrenia*/etiology

  • Source: Psychological medicine [Psychol Med] 2023 Aug; Vol. 53 (11), pp. 4990-5000. Date of Electronic Publication: 2022 Jul 12.Publisher: Cambridge University Press Country of Publication: England NLM ID: 1254142 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
  • 1-10 of  421 results for ""Schizophrenia""